September 28, 2023, Cleveland: New Cleveland Clinic -led research shows commonly used COVID-19 anti-viral drugs Paxlovid (nirmatrelvir) and Lagevrio (molnupiravir) reduce risk of hospitalization and death in high-risk patients with mild disease, even with Omicron subvariants. The observational study, published in JAMA Network Open , analyzed nearly 70,000 patients diagnosed with COVID-19 at Cleveland Clinic between April 2022 to February 2023. It found that nirmatrelvir lowered risk of death by 84% and molnupiravir by 77% compared to no treatment.

https://www.miragenews.com/paxlovid-legevrio-cut-covid-19-hospitalizations-1094037/

#miragenews